	US 12,005,080 B2
	Method for promoting proliferation of immune cells
Youguo Ling, Shanghai (CN); Hao Guo, Shanghai (CN); Xiaowen He, Shanghai (CN); Haili Ma, Shanghai (CN); Huijiao Li, Shanghai (CN); Huajing Wang, Shanghai (CN); Bi Ying, Shanghai (CN); and Huanfeng Yang, Shanghai (CN)
Assigned to Oricell Therapeutics Co., Ltd., Shanghai (CN)
Appl. No. 17/040,865
Filed by Oricell Therapeutics Co., Ltd., Shanghai (CN)
PCT Filed Mar. 25, 2019, PCT No. PCT/CN2019/079576 § 371(c)(1), (2) Date Sep. 23, 2020, PCT Pub. No. WO2019/184886, PCT Pub. Date Oct. 3, 2019.
Claims priority of application No. 201810251875.7 (CN), filed on Mar. 26, 2018.
Prior Publication US 2021/0106620 A1, Apr. 15, 2021
Int. Cl. A61K 35/17 (2015.01); A61P 35/00 (2006.01); C07K 14/705 (2006.01); C12N 5/0783 (2010.01); C12N 15/86 (2006.01)

CPC A61K 35/17 (2013.01) [A61P 35/00 (2018.01); C07K 14/705 (2013.01); C12N 5/0636 (2013.01); C12N 15/86 (2013.01); C12N 2740/15043 (2013.01)]

9 Claims

1. A genetically modified human immune cell, wherein the genetic modification up-regulates an expression of a low density lipoprotein receptor-associated protein or fragment thereof in the genetically modified immune cell, wherein the low density lipoprotein receptor-associated protein is low density lipoprotein receptor-associated protein 6 or the low density lipoprotein receptor-associated protein 5, wherein the low density lipoprotein receptor-associated protein or fragment thereof comprises an intracellular region of the low density lipoprotein receptor-associated protein, wherein the low density lipoprotein receptor-associated protein or fragment thereof comprises an amino acid sequence as set forth in any one of SEQ ID NO: 22, 24, 26, and 28, or an amino acid sequence having at least 80% homology thereof.